Main content area

Preoperative serum visfatin levels and prognosis of breast cancer among Chinese women

Li, Xiao-Yang, Tang, Shao-Hua, Zhou, Xiao-Cong, Ye, Ying-Hai, Xu, Xue-Qin, Li, Ri-Zeng
Peptides 2014 v.51 pp. 86-90
Chinese people, biomarkers, blood serum, breast neoplasms, cytokines, death, enzyme-linked immunosorbent assay, graphs, metastasis, mortality, multivariate analysis, nicotinamide phosphoribosyltransferase, nutritional status, patients, prognosis, surgery, women
Visfatin is identified a pro-inflammatory cytokine and its serum level is increased in various cancers. This study aimed to evaluate the prognostic value of preoperative serum visfatin level in breast cancers. Preoperative serum visfatin levels of 248 patients with breast cancer and serum visfatin levels of 100 healthy individuals and 100 benign women controls were determined using enzyme-linked immunosorbent assay. Unfavorable outcome was defined as first local recurrence, distant metastasis, second primary cancer of another organ, or death from any cause. Disease-free survival was defined as the time between surgery and the date of unfavorable outcome whichever appeared first. Overall survival was defined from surgery to death for any cause. The association of serum visfatin level with outcomes including mortality, unfavorable outcome, disease-free survival and overall survival was investigated by univariate and multivariate analyses. Preoperative serum visfatin level was substantially higher in patients than in healthy subjects and benign controls respectively. Elevated preoperative serum level of visfatin was identified an independent predictor of mortality, unfavorable outcome, disease-free survival and overall survival. Receiver operating characteristic curve analysis showed that serum level visfatin had high predictive value for mortality and unfavorable outcome. Thus, our results suggest that high preoperative serum visfatin level is associated with poor patient outcomes as well as may play a role as prognostic biomarker in breast cancer survival.